CLINICAL RESPONSES OF SARILUMAB BASED ON RHEUMATOID FACTOR AND ANTI- CYCLIC CITRULLINATED PEPTIDE AUTOANTIBODY STATUS IN PATIENTS WITH RHEUMATOID ARTHRITIS